Under the agreement, Cicel has committed to purchasing three Renaissance systems to pursue regulatory clearance from the State Food and Drug Administration in China and establish marketing activities there. The company expects regulatory clearance to take two years, and Cicel will have exclusive rights to market and distribute the system for the following three years.
More Articles on Orthopedic Devices:
TranS1 Reports 32% Drop in 4Q Revenue
Cleveland Clinic to Spin Off Orthopedic Preplanning Software
Titan Spine Expands to Europe With Subsidiary
Mazor Signs Distribution Agreement With Cicel Science & Technology for Chinese Market
Mazor Robotics announced it signed a distribution agreement with Cicel Science & Technology to distribute the company’s Renaissance robotic spinal system in China.
How 3 systems are improving patient flow and workforce alignment at infusion centers
Recommended Whitepaper